| Title |
A review of Neuropathic Pain: From Guidelines to Clinical Practice
|
|---|---|
| Published in |
Pain and Therapy, November 2017
|
| DOI | 10.1007/s40122-017-0087-0 |
| Pubmed ID | |
| Authors |
Giorgio Cruccu, Andrea Truini |
| Abstract |
Neuropathic pain is a chronic condition representing a significant burden for patients, society, and healthcare systems. The prevalence of neuropathic pain in the general population has been estimated at 7-8% and is expected to increase in the future. Neuropathic pain differs from nociceptive pain and requires a different therapeutic approach; and the management of neuropathic pain is complicated and challenging. This chapter discusses clinical practice guidelines for neuropathic pain and their usefulness in clinical practice. Pfizer, Italy. |
X Demographics
The data shown below were collected from the profiles of 29 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 24% |
| Canada | 3 | 10% |
| Saudi Arabia | 2 | 7% |
| Italy | 2 | 7% |
| Singapore | 1 | 3% |
| United Kingdom | 1 | 3% |
| Australia | 1 | 3% |
| France | 1 | 3% |
| Mexico | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 9 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 24 | 83% |
| Practitioners (doctors, other healthcare professionals) | 5 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 346 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 346 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 46 | 13% |
| Student > Bachelor | 39 | 11% |
| Other | 36 | 10% |
| Researcher | 28 | 8% |
| Student > Doctoral Student | 27 | 8% |
| Other | 73 | 21% |
| Unknown | 97 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 110 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 30 | 9% |
| Neuroscience | 28 | 8% |
| Nursing and Health Professions | 17 | 5% |
| Agricultural and Biological Sciences | 15 | 4% |
| Other | 40 | 12% |
| Unknown | 106 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 April 2023.
All research outputs
#1,035,350
of 24,770,025 outputs
Outputs from Pain and Therapy
#34
of 472 outputs
Outputs of similar age
#23,795
of 449,377 outputs
Outputs of similar age from Pain and Therapy
#2
of 10 outputs
Altmetric has tracked 24,770,025 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 472 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 449,377 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.